Cyclacel(CYCC)

Search documents
Cyclacel(CYCC) - 2019 Q2 - Quarterly Report
2019-08-13 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ...
Cyclacel(CYCC) - 2019 Q1 - Earnings Call Transcript
2019-05-14 23:21
Start Time: 16:30 January 1, 0000 4:50 PM ET Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2019 Earnings Conference Call May 14, 2019, 16:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO and Secretary Judy Chiao - VP, Clinical Development and Regulatory Affairs Alexander Fudukidis - IR, Russo Partners LLC Conference Call Participants Wangzhi Li - Ladenburg Thalmann & Co. Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter ...
Cyclacel(CYCC) - 2019 Q1 - Quarterly Report
2019-05-14 21:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 000-50626 | --- | --- | |--------------------------------------------------------------------------------------------- ...
Cyclacel(CYCC) - 2018 Q4 - Annual Report
2019-03-28 20:28
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 00-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91-1707622 (State or Other Jurisdiction of Incorp ...